Pyrazinobutazone | CAS#4985-25-5 | anti-inflammatory

MedKoo Cat#: 461159 | Name: Pyrazinobutazone

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Pyrazinobutazone is an antipyrene derivative which has anti-inflammatory properties.

Chemical Structure

Pyrazinobutazone

CAS#4985-25-5

Theoretical Analysis

MedKoo Cat#: 461159

Name: Pyrazinobutazone

CAS#: 4985-25-5

Chemical Formula: C23H30N4O2

Exact Mass: 394.2369

Molecular Weight: 394.51

Elemental Analysis: C, 70.02; H, 7.67; N, 14.20; O, 8.11

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Pyrazinobutazone; Carudol; DB 139; DB-139; DB139; Ranoroc;

IUPAC/Chemical Name

4-butyl-1,2-diphenylpyrazolidine-3,5-dione compound with piperazine (1:1)

InChi Key

HWGAOXKGTHUMFZ-UHFFFAOYSA-N

InChi Code

InChI=1S/C19H20N2O2.C4H10N2/c1-2-3-14-17-18(22)20(15-10-6-4-7-11-15)21(19(17)23)16-12-8-5-9-13-16;1-2-6-4-3-5-1/h4-13,17H,2-3,14H2,1H3;5-6H,1-4H2

SMILES Code

CCCCC1C(N(c2ccccc2)N(c3ccccc3)C1=O)=O.C4CNCCN4

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 394.51 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Maria VA, da Silva JA, Victorino RM. Agranulocytosis and liver damage associated with pyrazinobutazone with evidence for an immunological mechanism. J Rheumatol. 1989 Nov;16(11):1484-5. PubMed PMID: 2600947. 2: Dorado Bris JM, Aragues Montañes M, Sols Candela M, Garcia Diez A. Contact sensitivity to pyrazinobutazone (Carudol) with positive oral provocation test. Contact Dermatitis. 1992 May;26(5):355-6. PubMed PMID: 1395605. 3: Nove-Josserand G, Philippe LP, Ortonne JP, Gaillarde B, Pugiat M, Plauchu M. [Value of pyrazinobutazone in the treatment of various inflammatory conditions]. Lyon Med. 1972 Mar 26;227(6):587-90. French. PubMed PMID: 4538275. 4: Gaillarde B, Ortonne JP, Pugeat M, Plauchu M. [Value of pyrazinobutazone in the treatment of different inflammatory states]. J Med Lyon. 1972 Oct 5;53(234):1315-6 passim. French. PubMed PMID: 4539046. 5: Fournie A, Ayrolles C. [Pyrazinobutazone in rheumatology (Clinical study of 50 cases)]. Rhumatologie. 1972 Aug-Sep;24(7):287-91. French. PubMed PMID: 4540383. 6: Giroud MM, Maccotta. [Personal experimentation with pyrazinobutazone in dentistry]. Inf Dent. 1973 Mar 29;55(13):29-31. French. PubMed PMID: 4515315. 7: Commissionat Y, Daieff CY. [Pyrazinobutazone its activity in stomatology]. Rev Odontostomatol (Paris). 1973 Jan-Feb;20(1):77-8. French. PubMed PMID: 4516776. 8: Naudy F. [Value of pyrazinobutazone in long term treatment of chronic pain syndromes in the aged]. Therapeutique. 1973 May-Jun;49(5):379-83. French. PubMed PMID: 4205634. 9: von Bruchhausen V, Lohmann H, O'sváth J. The pharmacokinetic profile of pyrazinobutazone in man. Arzneimittelforschung. 1978;28(12):2337-43. PubMed PMID: 582952. 10: Toussaint J, Vermeire M. [Diffractometric study of pyrazinobutazone and related compounds]. Ann Pharm Fr. 1974 Jun;32(6):383-90. French. PubMed PMID: 4433140. 11: Le Chevallier PL. [The anti-inflammatory clinical effects of pyrazinobutazone (study of 44 cases with principally rheumatologic indications)]. Rhumatologie. 1972 Mar;24(3):91-100. French. PubMed PMID: 4538813. 12: Nicolas P. [Pyrazinobutazone in conservative dentistry]. Chir Dent Fr. 1971 Dec 8;41(93):61-2. French. PubMed PMID: 5291811. 13: Delhaye JP, Famaey JP. [Clinical evaluation in 42 rheumatic patients of a new pyrazole derivative: pyrazinobutazone or Carudol]. J Dent Assoc S Afr. 1973 Jan-Feb;28(1):14-22. French. PubMed PMID: 4542571. 14: Herzer P, Lemmel EM. Inhibition of granulocyte function by prednisolone and non-steroid anti-inflammatory drugs. Quantitative evaluation with NBT test and its correlation with phagocytosis. Immunobiology. 1980 Apr;157(1):78-88. PubMed PMID: 6894133. 15: Alessandrini A, Gemini R. [Comparative clinical study of the efficacy of and tolerance for lysine para-isobutylphenyl propionate in parallel with indomethacin and pyrasanone]. Clin Ter. 1980 Jul 31;94(2):137-47. Italian. PubMed PMID: 6450020. 16: Bantz W. [Ranoroc in the treatment of degenerative joint and spinal diseases]. Med Welt. 1980 Nov 7;31(45):1636-8. German. PubMed PMID: 6893852. 17: Kafarnik D, Semmler U, Pfannenstiel P, Miehlke K. [Comparative drug therapy study with scintigraphic control research]. Z Rheumatol. 1981 Mar-Apr;40(2):62-5. German. PubMed PMID: 6895140. 18: Baldi C, D'Ajello M, Balbi GC. [Treatment of dysmenorrhea with Pyrasanone]. Minerva Ginecol. 1983 Apr;35(4):247-50. Italian. PubMed PMID: 6350940. 19: Batko B. [Phenylbutazone derivatives and duodenal extrabulbar ulcer]. Wiad Lek. 1979 Dec 1;32(23):1707-10. Polish. PubMed PMID: 583380.